Efficacy of adalimumab for Crohn’s disease in real clinical practice


Cite item

Full Text

Abstract

Aim. To evaluate the efficacy and safety of adalimumab (ADA) in patients with Crohn’s disease (CD) treated at the Department of Inflammatory Bowel Diseases, Moscow Clinical Research and Practical Center, and to determine the predictors of a therapy response. Subjects and methods. All the patients with CD treated with ADA were followed up for at least 6 months or until the drug was discontinued. Therapeutic effectiveness was evaluated at 4 weeks and 6 months after the initiation of treatment and at the end of a follow-up. Complete intestinal mucosal healing was assessed at 3 and 12 months following treatment initiation. Univariate and multivariate analyses were used to determine the predictors of treatment response. Results. A clinical analysis covered 70 patients (57.1% male); the follow-up period averaged 112 weeks. Perianal fistulas were at baseline established in 22 (31.4%) patients with CD. 12 (17.4%) patients had been previously treated with infliximab (INF), 7 of them discontinued the drug for secondary loss of response and 5 for adverse reactions. 68 (97.1%) patients responded to an induction course of ADA. At 4 weeks, 6 months, and at the end of the follow-up, clinical remission occurred in 66.7, 80.4 and 67.4 % of patients with luminal CD and in 45.4, 36.5, and 36.4% of those with perianal CD, respectively. At 3 and 12 months and at the end of the follow-up, there was complete healing of the intestinal mucosa in 23.5, and 41.2 and 29.5% of cases, respectively. Six (8.8%) patients responding to the induction course needed to be optimized with ADA to 40 mg weekly. The time interval between treatment initiation and dose optimization averaged 30 weeks (range 12-120 months). There were 15 (21,4%) adverse events that were responsible for ADA discontinuation in 3 (4,2%) patients. Conclusion. The findings demonstrate the efficacy and safety of ADA used in clinical practice.

About the authors

O V Knyazev

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

A V Kagramanova

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

I N Ruchkina

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

N A Fadeeva

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

A A Lishchinskaya

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

O N Boldyreva

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

E Yu Zhulina

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

P L Shcherbakov

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

N V Orlova

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

M V Kirova

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

A I Parfenov

Московский клинический научно-практический центр Департамента здравоохранения Москвы

Москва, Россия

References

  1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:523-644.
  2. Sartor RB, Hoentjen F. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. Mucosal Immunology. 2005;30:681-701.
  3. Клинические рекомендации по диагностике и лечению взрослых больных язвенным колитом. 2013. 22 стр. ООО «Российская гастроэнтерологическая ассоциация», ООО «Ассоциация колопроктологов России» и Общества по изучению воспалительных заболеваний кишечника при Ассоциации колопроктологов России.
  4. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs. 2004;64:1766-1767.
  5. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
  6. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
  7. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
  8. Panaccione R, Colombel JF, Sandborn WJ, D’Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013;38(10):1236-1247. doi: 10.1111/apt.12499. Epub 2013 Sep 22. PMID: 24134498
  9. Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P.Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17(1):141-151. doi: 10.1002/ibd.21328
  10. Feagan BG, Panaccione R, Sandborn WJ, D’Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008;135(5):1493-1499. doi: 10.1053/j.gastro.2008.07.069
  11. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
  12. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007;25:675-680.
  13. Lуpez Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Dнaz-Rubio M. Adalimumab induction and maintenance therapy for Crohn’s disease. An open-label study. Rev Esp Enferm Dig. 2008;100:676-681.
  14. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007;25:675-680.
  15. Dewint P,Hansen BE, Verhey E, Oldenburg B, Hommes DW,Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292-299. doi: 10.1136/gutjnl-2013-304488
  16. Castaño-Milla C, Chaparro M, Saro C, Barreiro-de Acosta M, García-Albert AM, Bujanda L, Martín-Arranz MD, Carpio D, Muñoz F, Manceñido N, García-Planella E, Piqueras M, Calvet X, Cabriada JL, Botella B, Bermejo F, Gisbert JP. Effectiveness of adalimumab in perianal fistulas in Сrohn’s disease patients naive to anti-TNF therapy. J Clin Gastroenterol. 2015;49(1):34-40. doi: 10.1097/MCG.0000000000000169

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies